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Abstract 
Background: A subgroup of those with bipolar spectrum disorders experience ongoing mood fluctuations out‑
side of full episodes. We conducted a randomised, controlled feasibility study of a Dialectical Behavioural Therapy‑
informed approach for bipolar mood fluctuations (Therapy for Inter‑episode mood Variability in Bipolar [ThrIVe‑B]). 
Our study aimed to examine the feasibility and acceptability of a future definitive trial evaluating the clinical and cost 
effectiveness of the ThrIVe‑B programme. Participants were required to meet diagnostic criteria for a bipolar spectrum 
disorder and report frequent mood swings outside of acute episodes. They were randomised to treatment as usual 
(control arm) or the ThrIVe‑B intervention plus treatment as usual (intervention arm). Follow‑up points were at 3, 6, 
9 and 15 months after baseline, with 9 months as the primary end point. To evaluate feasibility and acceptability we 
examined recruitment and retention rates, completion rates for study measures, adverse events and feedback from 
participants on their experience of study participation and therapy.
Results: Of the target 48 participants, 43 were recruited (22 in the intervention arm; 21 in the control arm), with 
a recruitment rate of 3.9 participants per month. At 9 months 74% of participants engaged in research follow‑up 
assessment, exceeding the pre‑specified criterion of 60%. There were no serious concerns about the safety of the 
research procedures or the intervention. On one of the four candidate primary outcome measures, the 95% CI for the 
between‑group mean difference score excluded the null effect and included the minimal clinically important differ‑
ence, favouring the intervention arm, whilst on no measure was there evidence of deterioration in the intervention 
arm relative to the control arm. Attendance of the intervention (50% attending at least half of the mandatory sessions) 
was below the pre‑specified continuation criterion of 60%, and qualitative feedback from participants indicated areas 
that may have hampered or facilitated engagement.
Conclusions: It is broadly feasible to conduct a trial of this design within the population of people with frequent 
bipolar mood swings. Changes should be made to the therapy to increase uptake, such as simplifying content and 
considering individual rather than group delivery.
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the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds 
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Background
Within bipolar spectrum disorders, ongoing instability of 
mood (henceforth referred to as bipolar mood instabil-
ity [BPMI]) is characteristic of Cyclothymic Disorder, yet 
can also be experienced by individuals with Bipolar dis-
order I or II outside of acute episodes of mania or depres-
sion (Bonsall et  al. 2012). BPMI may be an important 
target for intervention in its own right: as well as Cyclo-
thymic Disorder being a risk factor for future episodes 
of mania and depression (Akiskal et  al. 1977), BPMI 
between episodes is associated with increased psychiatric 
comorbidity, reduced psychosocial functioning and lower 
self-reported quality of life (Faurholt-Jepsen et  al. 2019; 
Henry et  al. 2008; Gershon and Eidelman 2015; Streji-
levich et al. 2013).
Trials of medication for Bipolar disorders rarely target 
BPMI specifically and consequently there is no gener-
ally accepted pharmacological treatment strategy for this 
aspect of the condition. Similarly, trials of psychologi-
cal therapies for Bipolar disorders have tended to focus 
upon treating acute depression or reducing risk of relapse 
rather than reducing mood instability. Whilst a small 
number of studies have tested psychological interven-
tions for Cyclothymic Disorder or given consideration 
to BPMI within Bipolar disorder (Fava et al. 2011; Hales 
et  al. 2018; Totterdell and Kellett 2008; Totterdell et  al. 
2012), none of these have tested an intervention specifi-
cally developed for BPMI across the Bipolar Spectrum. 
Here we report a randomised controlled feasibility study 
of such an approach.
Our approach is informed by Dialectical Behaviour 
Therapy (Linehan 1993) which was originally devel-
oped for another patient group with ongoing instability 
of mood, those with a diagnosis of Emotional Unstable 
Personality Disorder (EUPD). DBT teaches skills both in 
acceptance of situations and emotional responses, and in 
selection of adaptive behavioural responses to emotional 
and situational triggers, and has been found to be effec-
tive in EUPD (Cristea et al. 2017). Whilst versions of DBT 
have been explored within those with Bipolar disorder in 
an open trial and two pilot randomised controlled tri-
als (Goldstein et al. 2007, 2015; Dijk et al. 2013) none of 
these have specifically targeted those experiencing BPMI.
To address this gap we developed the ThrIVe-B pro-
gramme (Therapy for Inter-episode mood Variability 
in Bipolar) as a bespoke approach for those with BPMI. 
In this approach participants are invited to reflect 
upon their behavioural response to extreme mood and 
activation states day-to-day, modifying this where neces-
sary, congruent with evidence that unhelpful behavioural 
response to mood is associated with bipolar symptom 
exacerbation (Lam et al. 2001; Palmier-Claus et al. 2016). 
In DBT this is achieved by building mindful aware-
ness skills and through giving participants a framework 
through which to appraise their emotional responses 
and to develop alternative ways of relating to and man-
aging these. In ThrIVe-B we further developed this pro-
cess with respect to hypomanic and depressive feelings. 
ThrIVe-B also attended to triggers of mood dysregula-
tion: circadian rhythm disruption has been found to pre-
cede the onset of Bipolar episodes (Takaesu 2018) whilst 
social support appears to be associated with a more 
favourable course of symptoms (Cohen et al. 2004; John-
son et  al. 1999) therefore we utilised elements of DBT 
that promote stable routine and interpersonal problem-
solving and communication, and developed elements 
around mobilising social support.
Initial evaluation of the ThrIVe-B programme in an 
uncontrolled feasibility study (N = 12) (Wright et  al. 
2020) found it to be acceptable to recipients: 75% com-
pleted therapy. Consistent with potential for clinical 
benefit, reliable improvement in depression, anxiety and 
general mental health symptoms was observed in least 
half the participants, with very few instances of reliable 
deterioration on any measure. Participant feedback sup-
ported this, and congruent with the key putative mech-
anism of change, participants described gaining the 
ability to step back from intense feelings and make bet-
ter choices. There were no trial-related serious adverse 
events or concerns about therapy safety.
To resolve uncertainties in the design and delivery 
of a future efficacy trial, the present study was a ran-
domised, controlled feasibility study across two sites 
(Devon and Cumbria). Our objectives were to: (i) estab-
lish recruitment pathways and trial teams in two sites; 
(ii) establish the number of participants initially identi-
fied, approached, consented, randomised and completed; 
(iii) establish the acceptability and experience of the trial 
process to participants, including randomisation and 
completion of outcome measures; (iv) further assess the 
acceptability of the treatment via qualitative interviews 
and, based on input from trial participants and clinicians, 
to further refine and develop the treatment manual and 
the procedures for training, supervising and assessing the 
competence of trial therapists; (v) assess the performance 
of selected candidate primary outcome measures for a 
Trial registration ISRCTN: ISRCTN54234300. Registered 14th July 2017, http:// www. isrctn. com/ ISRCT N5423 4300
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future definitive trial with respect to level of acceptabil-
ity to participants and participant-perceived relevance 
and value; (vi) measure data completeness at follow-up, 
SD of the likely primary outcome measure, and describe 
the variability of the comparator condition, treatment 
as usual (TAU), across individuals and sites; (vii) pilot 
a measure of resource use and to assess the feasibility 
and acceptability of candidate health outcome measures 
for economic evaluations; and (viii) identify, measure 
and cost the resources used and needed to deliver the 
intervention.
We also aimed to evaluate whether the following con-
tinuation criteria were met prior to planning a future 
definitive trial: (i) trial participation does not lead to seri-
ous negative consequences (unexpected serious adverse 
reaction) for participants; (ii) any serious concerns about 
the acceptability and feasibility of the trial procedures 
can be rectified prior to a full trial; (iii) follow-up data at 
9 months are available for at least 60% of participants; (iv) 
at least 60% of patients in the intervention group com-
plete treatment (attend at least 50% of possible sessions).
Method
Trial design
We conducted a feasibility study with a two-arm, ran-
domised, parallel, controlled trial design. Participants 
were randomised in a 1:1 ratio to TAU only (control arm) 
or TAU plus the ThrIVe-B programme (intervention 
arm). Outcome measures were administered at baseline 
and at 3, 6, 9 and 15  months after randomisation. The 
primary end point was predetermined to be at 9 months. 
The full trial protocol is reported elsewhere (Wright et al. 
2018).
A panel of individuals with lived experience of mood 
disorders advised on study design and delivery through-
out the trial.
Participants
Participants were required to be aged 18 years or older, 
with a diagnosis of BD (I, II, other specified BD) or 
Cyclothymic Disorder, according to the criteria in the 
Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-V) (American Psychiatric Associa-
tion 2013), and to have a period of at least 2 days during 
which symptom criteria for hypomania/mania were met. 
They were required to have current BPMI, defined as 
either meeting DSM-V criteria 1 and 2 for Cyclothymic 
Disorder, or having a score of at least 1.3 [the mean for 
individuals with Bipolar disorder in previous research 
(Henry et al. 2008)] on the bipolar subscale of the short 
form of the Affective Lability Scale (ALS) (Oliver and 
Simons 2004). Participants had to be willing to engage in 
psychological therapy that focusses primarily on ongoing 
mood instability and its consequences, and be willing and 
able to attend scheduled group therapy sessions. Suffi-
cient competency in English to be able to complete study 
measures without the need for translation was required, 
as was registration with a primary care physician in the 
study catchment area. Exclusion criteria included current 
substance dependence, other ongoing psychological ther-
apy for BD at study entry, lack of capacity to consent to 
treatment or research participation, and acute mania or 
depression (DSM-V). Participants engaging in frequent, 
significant self-harming behaviour, at high risk of sui-
cide, or posing a significant risk to other group members 
were not eligible. Initially patients receiving ongoing, 
co-ordinated care in secondary mental health services 
were excluded from participation because the ThriVe-B 
programme was aimed at those at the interface between 
primary and secondary care, however this criterion was 
removed at month 9 of the 11 month recruitment phase 
to facilitate recruitment.
Participants were recruited from two sites in the 
United Kingdom, Cumbria and Devon. Both are rela-
tively rural however Cumbria has a population density 
less than half that of Devon’s. Recruitment was via pri-
mary care services, secondary care mental health services 
and self-referral. Following an expression of interest, par-
ticipants providing written agreement to be contacted 
by the study team were sent information about the study 
and invited to attend a baseline eligibility assessment 
interview. Those not referred from secondary care (and 
thus who had not recently participated in a specialist Psy-
chiatric assessment) completed a telephone screening 
interview prior to the eligibility assessment to increase 
the likelihood that those invited for a time-consuming 
face-to-face assessment would be eligible. At the eligi-
bility assessment written, informed consent was sought, 
eligibility criteria were checked and baseline measures 
completed.
Planned sample size
On the basis of our previous work (Wright et  al. 2020) 
we estimated an attrition rate of 17% with respect to the 
9 month primary end point. A sample of 48 would allow 
estimation of this level of attrition for a future definitive 
trial with a precision of ± 15% with 95% certainty. The 48 
participants (24 per arm) would represent recruitment to 
three ThrIVe-B groups at full capacity (8 per group: 2 in 
Devon and 1 in Cumbria).
Intervention
The intervention (ThrIVe-B) was delivered in addi-
tion to TAU. The content of the ThrIVe-B programme 
is described in detail in the logic model in Additional 
file  1. In brief, modules covered Mindful Awareness, 
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Day to Day Mood Regulation. Tolerating Intense Moods, 
and Wise Relationships The programme consisted of 15 
weekly group meetings and up to eight individual ses-
sions of up to 45 min held either face-to-face or by tel-
ephone, according to participant preference for modality, 
number and duration. All participants were expected to 
attend the initial and final individual meeting. There was 
a group “booster” session 3 months after the final group 
meeting, and midway through the programme partici-
pants were offered a “supporters” session which friends 
or family could attend. To help generalisation of learning, 
participants were given a folder of written materials. In 
addition we used a custom-built smartphone application 
(‘ThrIVe-B app’) to prompt participants to use skills at 
times of extreme mood, between therapy sessions. The 
app asked participants to rate their mood from − 10 to 
+ 10 each day between 0 and 10 times, with number of 
ratings per day determined by the user. Users specified 
‘high’ and ‘low’ mood thresholds and when these were 
surpassed, users saw a feedback screen containing advi-
sory messages they had pre-programmed either alone or 
with therapist support, which could contain techniques 
from the therapy programme (see Additional file  2). A 
version of this app, with reduced functionality, was also 
used to monitor mood stability over 7-day periods at 
baseline and at follow-up for all participants.
Therapy was delivered by four qualified mental health 
professionals with previous specialist training in cogni-
tive behavioural therapy and related approaches (two 
therapists per group). A 5 day bespoke, face-to-face train-
ing programme was provided by the main author of the 
ThrIVe-B therapy protocol, which covered background 
information about Bipolar disorder, the therapeutic 
stance within DBT-informed approaches, therapy com-
ponents, and skills in group facilitation. Weekly supervi-
sion occurred throughout therapy delivery. Before each 
group session participants completed the Beck Depres-
sion Inventory (Beck et  al. 1961) and Altman Scale for 
Rating Mania (Altman et al. 1997).
Participants in the TAU arm received their usual NHS 
care, with no stipulation from the trial regarding the min-
imum constituents of this. In addition, in order that the 
two arms were broadly equivalent in time spent using the 
app between assessment points, those in the TAU arm 
were invited to use it for mood monitoring only (no addi-
tional therapeutic functionality) between months 3 and 9. 
As per the intervention arm, participants could set num-
ber of alerts per day from 0 to 10. Other than the experi-
mental intervention no treatments were withheld.
Outcomes
Primary outcome measures. Numbers of patients identi-
fied, approached, consented, randomised and completed 
were used to assess feasibility, as was participant attri-
tion from the trial and from treatment. Acceptability was 
assessed by questionnaires at baseline, 9  month follow-
up and on ineligibility or withdrawal from the study. 
Items with quantitative ratings at 9  month follow-up 
were rated on a five point scale and asked about accept-
ability and satisfaction (anchored from “not at all” to 
“extremely”) and likelihood of recommending the trial to 
eligible friends and family. To assess patient valuation of 
outcomes, at the 9-month follow-up point participants 
were asked to rank the four candidate outcome meas-
ures (see below) and a measure of anxiety symptoms, 
the Generalised Anxiety Disorder 7-item scale (GAD-7) 
(Spitzer et al. 2006) in order of priority, in terms of where 
they would most want to see change following psycho-
logical treatment. Participants were also asked to esti-
mate the smallest change on each measure that would 
feel meaningful.
A subset of 14 participants from both sites took part 
in a semi-structured interview exploring their experi-
ences of the research study and therapy in more detail. 
Referring clinicians were asked for their views of the 
therapy and research process using a brief survey form, 
and ThrIVe-B therapists took part in an interview about 
their experiences and views of the therapy, training and 
supervision.
Adherence to treatment was measured in terms of 
number of therapy sessions attended; because some indi-
vidual sessions were optional, “possible sessions” (con-
tinuation rule 4) was defined as all 15 group sessions, 
booster session and initial and final individual sessions 
(18 sessions in total).
The ThrIVe-B app was used to gather data on momen-
tary mood in order to assess mood stability. All partici-
pants were invited to use the app for 1 week at baseline 
and at 9-month follow-up, to give comparable 1  week 
periods of mood stability data that did not overlap with 
periods of therapeutic app use. Mood stability measured 
by the ThrIVe-B app is a potential secondary outcome 
in a definitive trial, therefore we tested the feasibility 
and acceptability of gathering these data, as indicated by 
completion rates and participant feedback.
Secondary outcome measures. The following were can-
didate primary outcome measures for a future definitive 
trial and were completed at baseline and all follow-up 
points: the Patient Health Questionnaire 9-item scale 
(PHQ-9) (Spitzer et  al. 1999) which measures depres-
sive symptoms; the short-form Affective Lability Scale; 
the Bipolar Recovery Questionnaire (BRQ) (Jones et  al. 
2013); and the brief Quality of Life in Bipolar disorder 
scale (QoL-BD) (Michalak et  al. 2010). Participants also 
completed the GAD-7. At baseline, 9 and 15 months, the 
Bech Mania Rating Scale (BMRS) (Bech et al. 1978), the 
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Hamilton Depression Rating Scale (HDRS) (Hamilton 
1986) (both observer-rated), and the Brief Adherence 
Rating Scale for medication adherence (BARS) (Byerly 
et  al. 2008) were completed, as was relevant sections of 
the Structured Clinical Interview for DSM-V (First et al. 
2014). This was used both to assess eligibility criteria, and 
to identify affective episodes during the follow-up period.
To assess feasibility of health outcome measures for a 
future cost-effectiveness analysis was assessed with two 
measures: the EuroQoL 5-dimension 3-level (EQ-5D-3L) 
(Oppe and Devlin 2007),1 and the 36-item Short Form 
Health Survey (SF-36) (Garratt et  al. 1993), these were 
administered at baseline and follow-up points. In addi-
tion, participants were asked to complete a resource use 
questionnaire (last 6  months or since last assessment 
point) for assessing the feasibility of collecting accurate 
health and social service use. Finally information on 
resource use and costs of delivering the ThrIVE-B pro-
gramme were also collected.
Quantitative process measurement
Measurement of putative mechanisms of change was 
included in order to inform measurement in a definitive 
trial. These were completed at baseline and all follow-up 
points. We included measures of impulsive behavioural 
response to high and low mood (Positive and Nega-
tive Urgency, Premeditation, Perseverance, Sensation-
Seeking impulsive behaviour scales [UPPS-P] (Cyders 
et  al. 2007); Behavioral Activation in Depression Scale 
[BADS] (Kanter et al. 2007)) as this is a key process that 
ThrIVe-B aims to disrupt. In DBT this is achieved in part 
by building mindful awareness skills, hence we measured 
this using the Kentucky Inventory of Mindfulness Skills 
(KIMS) (Baer et  al. 2004). We assessed social rhythm 
stability using the adapted Social Rhythm Metric (SRM) 
(Monk et al. 1990) and emotional problem solving using 
the Means-Ends Problem Solving task (MEPS: baseline, 9 
and 15 months only) (Kehrer and Linehan 1996).
The schedule for administration of study measures is 
shown in Additional file 3.
Procedure
Prior to conducting the trial ethical approval was 
obtained from the National Research Ethics Service (Ref: 
219816) and local departmental research ethics commit-
tees. Assessments were face to face, by telephone, by post 
or online, dependent upon participant preference. In-
person contact was required at baseline and at months 9 
and 15 in order to complete the interview-based meas-
ures. At 9  months the questionnaire on experiences of 
the study was completed and a subset of participants 
completed the semi-structured interview.
Randomisation, concealment of allocation, and blinding
Participants were randomised on a 1:1 ratio, with mini-
misation by trial site and medication status (any medica-
tion for Bipolar disorder prescribed: yes/no). To ensure 
concealment, eligible participants were randomised via a 
validated password website hosted by Exeter Clinical Tri-
als Unit. The first ten participants were allocated using 
simple randomisation; the remainder were allocated 
using the minimisation procedure, maintaining a sto-
chastic element to the algorithm to allow concealment. 
Participants were randomised prior to the start of each 
therapy group, and informed by an unblinded researcher.
Researchers conducting follow-up assessments were 
blind to allocation and participants were reminded of this 
at each follow-up contact. All unblindings were recorded 
and where possible, researchers who remained blinded 
to that participant’s status conducted future follow-up 
assessments. All statistical analyses were performed by 
a statistician using groups indicated by an anonymised 
code.
Statistical and economic methods
The primary analyses were performed after 9-month 
follow-up. Further analyses were performed after the 
final 15-month follow-up. No interim analyses were con-
ducted. All analyses were on an intention-to-treat basis; 
included outcomes were reported according to ran-
domised allocation, regardless of the treatment actually 
received. No attempts to address missing data, such as 
multiple imputation, were made. The economic analysis 
took the NHS and social care perspective.
At 9-month follow-up only, an inferential analysis was 
performed for continuous outcomes only, reporting the 
relevant 95% CI for the between-group mean difference 
(intervention minus TAU), but no p value. Inferential 
analyses included the randomisation covariates of site 
and baseline medication status.
Qualitative analysis
Qualitative interviews and written responses on the 
feedback questionnaires were analysed using a frame-
work approach (Ritchie and Spencer 2002). A pre-
liminary set of a priori themes was drawn up, based on 
interview/questionnaire questions (e.g. expectations of 
therapy; most helpful aspects; unhelpful aspects). Data 
were entered onto a spreadsheet, creating a matrix of 
rows (participants) and columns (themes) and populat-
ing it with summarised responses. During the process, 
1 The National Institute of Health and Clinical Excellence preferred health-
related quality of life measure in adults for economic evaluations is EQ-5D. 
This study used the 3-level instead of the 5-level version stated in the original 
protocol.
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higher-order themes and sub-themes were inductively 
generated. These were then tabulated, with exemplary 





Recruitment took place over an 11  month period 
between August 2017 and July 2018, with follow-up 
ending in October 2019 after the final piece of data had 
been collected.
Recruitment and retention outcomes are shown in 
Fig. 1. Of 129 individuals who had initial contact with the 
research team, 77 (60%) were contactable for and com-
pleted the screening telephone call. Following this, 9 did 
not meet criteria, 11 were not contactable afterwards, 5 
declined to participate and 1 had already received a pre-
vious version of the approach. A total of 51 potential 
participants were assessed for eligibility. Following this, 
Fig. 1 CONSORT diagram of trial recruitment and retention
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four were not eligible, two were not contactable and two 
declined to participate. Of the 43 people randomised 22 
were allocated to the intervention arm and 21 to the TAU 
arm. Recruitment was above target at one site (Devon: 32 
planned, 34 actual) and below at the other (Cumbria: 16 
planned, 9 actual), resulting in an overall number slightly 
below our original target (43/48).
The overall randomisation rate for the study was 3.9 
participants per month. Within the two sites, this was 
3.8 per month in Devon (34 participants over 9 months) 
and 1.3 per month in Cumbria (nine participants over 
7 months).
Of those randomised 33 (77%) were informed about 
the study by their GP, 5 (12%) through contact with local 
mental health services, 4 (9%) through media and social 
media campaigns and 1 (2%) unknown.
Of those randomised to the intervention arm, 8 were 
allocated to the first Devon group, 9 to the second, and 5 
to the group in Cumbria.
Baseline data
The demographic and clinical characteristics of the sam-
ple are given in Table  1. Of 43 participants, 23 (53%) 
were female, with a median age of 44 years (range 20 to 
75 years). The majority of participants met research diag-
nostic criteria for Bipolar I disorder with the remain-
der meeting criteria for Bipolar II disorder. In terms of 
characterising the usual psychiatric care for our sample, 
of the 40 participants providing detailed information on 
this for the 6 months prior to study entry, 19 (48%) had 
contact with a Community Mental Health Team, 1 (3%) 
reported a psychiatric admission, 10 (25%) reported con-
tact with crisis services and 18 (45%) reported contact 
with a therapist, counsellor or psychologist. The majority 
of the sample (38/43: 88%) were prescribed medication 
for Bipolar disorder at study entry, and most participants 
were seen in primary care only for their mental health 
care.
At study entry participants reported mean depression 
and anxiety levels in the moderate range, and low levels 
of current mania symptoms (Table 2). Mean quality of life 
(QoL.BD) and sense of personal recovery (BRQ) scores 
for the sample were below but within one SD of those 
reported in the literature for individuals with Bipolar dis-
order (Bech et al. 1978; Hamilton 1986).
Trial and therapy retention of participants
We distinguish between research follow-up attrition and 
therapy attrition, as it was possible for participants to 
complete therapy and then opt not to complete research 
follow-up assessments, and vice-versa.
At 9-month follow-up 74% of participants (14 in 
intervention arm and 18 in TAU arm; 24 [71%] in the 
Devon site and 8 [89%] in the Cumbria site) provided 
at least partial follow-up data; 11/43 (26%; 95% CI 14 
to 41%) were lost to follow up. Five participants with-
drew in the period between randomisation and final 
follow-up (four in the intervention arm; one in the TAU 
arm); none were withdrawn by the research team. Fig-
ure 1 shows the number of participants returning data 
at each follow-up point.
Of the 22 participants allocated to receive the inter-
vention, 17 attended at least three sessions (in other 
words, attended beyond the first individual and first 
Table 1 Demographic and clinical characteristics of trial 
participants
a Minimum age set to 6 years
ThrIVe-B (n = 22) Treatment as 
usual (n = 21)
Total (N = 43)
Gender; n (%)
 Female 14 (64) 9 (43) 23 (53)
 Male 8 (36) 12 (57) 20 (47)
Age in years
 Mean (SD) 43.6 (13.0) 49.3 (14.5) 46.4 (13.9)
 Median [min, max] 43 [20, 68] 51 [24, 75] 44 [20, 75]
Ethnic group; n (%)
 White 22 (100) 20 (95) 42 (98)
 Asian 0 (0) 1 (5) 1 (2)
Prescribed medication for
 Bipolar disorder; 
n (%)
19 (86) 19 (90) 38 (88)
 Mood stabiliser 14 (63) 12 (57) 26 (61)
 Antipsychotic 10 (46) 14 (67) 24 (56)
 Antidepressant 7 (32) 8 (38) 15 (35)
Site; n (%)
 Devon 17 (77) 17 (81) 34 (79)
 Cumbria 5 (23) 4 (19) 9 (21)
In ongoing secondary care; n (%)
 Yes 2 (9) 4 (19) 6 (14)
 No 20 (91) 17 (81) 37 (86)
Age of depression 
 onseta; mean (SD), 








Age of mania onset; 









Bipolar I disorder; 
n (%)
19 (86) 18 (86) 37 (86)
Bipolar II disorder; 
n (%)
3 (14) 3 (14) 6 (14)
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group session).2 Of the remaining five, two moved out 
of the area at the start of the intervention period, one 
had a competing commitment, one decided the inter-
vention was not suited to them, and one did not attend 
for reasons unknown. Of the original 22 participants, 
11 (50%) completed treatment, defined as attending 
at least half the 18 “mandatory” sessions. In terms of 
group attendance per session this ranged from 1 to 8.
Data completion for the smartphone app was low: at 
baseline, 16 participants provided data for at least 7 days 
(mean days 10.7, SD 15.5). Between months 3 and 9, 10 
participants (6 intervention, 4 TAU) used the app at least 
once; at 9  months 3 TAU participants used the app at 
least once (no participants in the intervention group used 
the app at 9 months).
Acceptability
Quantitative acceptability data were available from 17 
participants (8 in the therapy arm, 9 in the TAU arm) 
at 9 months. Of these, 16 found the research process at 
least moderately acceptable, with 14/17 at least moder-
ately satisfied. Of the eight participants in the therapy 
arm who responded, seven rated therapy as “very” or 
“extremely” acceptable, and were at least “moderately” 
satisfied with therapy; one found therapy “slightly” 
acceptable/satisfactory.
Qualitative acceptability data were synthesised from 
four sources: acceptability surveys at 9  month follow-
up (n = 17), qualitative interviews at 9  month follow-up 
(n = 14, 8 in therapy arm), surveys of participant experi-
ence after the baseline assessment (n = 19) and surveys 
of those who declined to take part or were not eligible 
(n = 9).
Making a contribution to society, learning more, and 
having the chance to access a new therapy emerged as 
key motives for participation. With regard to the expe-
rience of being involved, some participants found the 
volume of measures challenging; participants also high-
lighted how important it was that the measures felt rel-
evant to them. Having a positive relationship with the 
research team was seen as important and was associated 
with a positive experience of interviews. Participants in 
the control group expressed some disappointment at not 
being offered therapy, whilst appreciating of the need 
for a control group in trials. Barriers to taking part in 
the study included cost of travel and childcare, and the 
level of commitment required. The smartphone app was 
used as part of both the research and therapy aspect of 
the study. Interruption of activities due to the alerts and 
direction of attention to negative feelings whilst making 
mood ratings were seen as downsides and several sug-
gestions were made for improvement. Some participants 
reported technical issues with the app which may have 
contributed to low rates of data return.
Analysis of qualitative feedback on the therapy itself 
(n = 8 interviews, n = 8 surveys) was organised under 
three main themes: interpersonal aspects of therapy 
(subdivided into group process and therapist style); 
therapy content and delivery modes, and where/how the 
therapy helped. A summary of themes and sub-themes 
with exemplar quotes is given in Additional file 4.
Participants valued the closed nature of the group 
(that the same group of people met each session) and 
the mutual support it generated, although some strug-
gled with particular group dynamics. Both the group and 
the therapist were instrumental in enabling participants 
to feel held and understood, which was key to a positive 
therapeutic experience. Therapist personality and style 
was seen as very important; authenticity was particularly 
valued and helped participants to feel that the material 
was coming from a person rather than from a textbook: 
“Yeah, [therapist] would give examples from her life 
which you felt were very genuine … it felt very genuine, 
and I could get on with that” (201: 4,6). The amount of 
information delivered was seen to be high; some found 
this problematic and were worried about overload, but 
reported that it was helped by the use of multiple modes 
of delivery and tools for repeating and retaining informa-
tion, such as handouts and booster sessions. Participants 
noted the importance of feeling that the material was rel-
evant and tailored to them, and that it was offered at the 
right time of life. Participants noted several areas of ben-
efit from the therapy, including greater understanding of 
the self, including re-evaluation of the self in a more posi-
tive or accepting way; greater understanding between 
the self and others; changes in behavioural responses to 
moods (even if the mood did not change), and broaden-
ing their range of activities.
Local clinicians (n = 8) saw DBT-informed therapy as 
appropriate for the client group, similarly the length of 
treatment and point of delivery in the care pathway. Cli-
nicians queried whether a group based approach could be 
delivered and accessed successfully in the health service, 
as patients might initially be put off by the prospect of a 
group-based approach, and whether extreme mood states 
might interfere with group work. Feedback from thera-
pists (n = 4) revealed overall high satisfaction with the 
techniques and materials, and with the potential to help 
this patient group, but there was also a sense of having a 
great deal of information to communicate to patients.
With regard to rankings of personal importance of the 
candidate primary outcome measures and GAD-7, the 
2 One participant in the TAU arm unintentionally received one session of 
ThrIVe-B content. They remained in the study.
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mean rankings were highest for the BRQ and ALS and 
lowest for the PHQ9. The GAD7 was ranked number 1 by 
the greatest proportion of participants (8/30: 27%), fol-
lowed by the BRQ and ALS (both 7: 23%). The median 
smallest meaningful change values for each of the five 
measures are given in Table 2: for each measure, values 
given by participants were widely distributed. This may 
represent genuine lack of consensus but may also sug-
gest that further refinement of the process of obtaining 
smallest meaningful change values is required in this 
population.
Study and therapy safety
Over the study period there were 48 adverse events (8 
prior to randomisation, 19 in the therapy arm and 18 in 
the TAU arm post randomisation). These included 32 
instances related to risk of suicide or self-harm (includ-
ing enactment of study risk protocol following reports of 
suicidal ideation, and any reported acts of self-harm or 
towards ending one’s life), six reports of distress during 
or after study procedures, eight physical health events 
requiring treatment and two psychiatric admissions. Five 
were serious adverse events, none of which were unex-
pected. It was judged that trial procedures (completion 
of questionnaires) may possibly have contributed to one 
of these events (low mood culminating in admission to 
hospital); the other serious adverse events were judged 
unrelated to the trial.
Candidate primary clinical outcomes
Mean scores on candidate primary and secondary out-
come measures at follow-up are given in Table  2. At 
9  months, the between group mean difference for BRQ 
was 349 (95% CI 107 to 591), with the intervention arm 
scoring higher (indicating greater personal recovery). 
The 95% CI included the minimum clinically important 
difference score of 200 found by the measure develop-
ers (Jones, personal communication), and excluded the 
null treatment effect. For the PHQ-9, there was minimal 
between group difference (− 0.2 (95% CI − 4.6 to 4.2)); 
the between-group differences for the ALS (−  1.6 (95% 
CI − 8.4 to 5.3) and QoL.BD (2.4 (95% CI − 5.2 to 9.9)) 
favoured the intervention arm but for all three measures 
the 95% CIs included the null treatment effect.
At 9-month follow-up, the between group mean dif-
ference for the Kentucky Inventory of Mindfulness Skills 
was 13.1 (95% CI 4.9 to 21.3), indicating higher self-
reported mindfulness skills in the intervention group, 
with the 95% CI excluding the null treatment effect. The 
remaining nine secondary outcomes all yielded a 95% CI 
that included the null treatment effect.
Completion rates were similar between EQ-5D-3L and 
SF-36 measures, but lower for the resource use measure. 
Table 3 displays aggregated data for the health states util-
ity values derived from the EQ-5D-3L and the SF-36. At 
9-months, the arms differed significantly with respect to 
SF-36 utility scores (0.11; 95% CI 0.01–0.20), favouring in 
the intervention arm. At 9 months no significant differ-
ence between arms was observed in health care resource 
use (Additional files 5 and 6). The cost of providing the 
ThrIVE-B intervention per participant was £806.29 
(Additional file 7).
Discussion
This randomised, controlled feasibility trial is the first to 
focus specifically upon people with ongoing mood insta-
bility within Bipolar Spectrum Disorders, and represents 
an important step in the development and testing of a 
novel psychological intervention for this population. In 
accordance with the study aims, we established recruit-
ment pathways and trial teams in two sites and gathered 
information on patient recruitment and attrition rates. 
The overall rate of randomisation of 3.9 participants per 
month supports the feasibility of a larger trial, recruit-
ing across a longer period and across multiple sites. This 
could be maximised by learning from experiences in 
the current trial, where one site recruited more success-
fully than the other. In particular, rural sites face greater 
challenges than do more urban ones when aiming to fill 
a therapy group with patients who have a relatively low-
prevalence condition. In this study we initially sought to 
recruit patients from primary care only; whilst this was 
the case for the majority of participants, a small number 
were in secondary care. Setting out to work with a larger 
number of GP practices per site, selecting sites with a 
track record of primary care mental health recruitment 
and including a generally publicised self-referral option 
should be a priority for future studies in this population.
All four candidate primary outcome measures were 
seen as similarly valuable by participants and had simi-
lar rates of completion: on this basis any of these could 
be suitable as a primary outcome measure in future tri-
als. Based on participant feedback about key areas of 
perceived change, it may be appropriate to select two pri-
mary outcome measures, one reflecting mood variability 
and another functioning or recovery. Rates of completion 
were similar across health economics measures.
Continuation criterion one (no unexpected serious 
adverse reactions to the therapy or research proce-
dures) was met. Completion rate of measures met con-
tinuation criterion three (follow up data at 9  months 
are available from at least 60% of participants), with 
no evidence of greater attrition in the control arm. 
Nevertheless some participants in both arms reported 
finding the self-report measures onerous; this could 
potentially be improved by reducing the number of 
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measures, using a more sophisticated online data col-
lection platform, and making more use of participant 
payment. Whilst participants reported many posi-
tive aspects of the therapy, overall therapy attendance 
rates were numerically lower than the previous open 
trial (Wright et  al. 2020), which may be the result of 
the imprecision inherent in estimates derived from 
small samples, but may also request variation in ease 
of recruitment in this multi-site trial. Nevertheless, as 
they were also below those specified a-priori in con-
tinuation rule four (at least 60% of patients complete at 
least 50% of sessions) improvement of the therapy con-
tent and delivery is required. Using a one-to-one rather 
than group-based method of delivery would increase 
accessibility to patients due to flexibility in schedul-
ing and the potential to conduct sessions by telephone 
when patients are unable to attend in person. Feed-
back from participants suggested that whilst there were 
some benefits of group-based delivery, therapist factors 
played a significant role in successful engagement with 
the therapy content, thus supporting the feasibility of 
one-to-one delivery. Responding to feedback from par-
ticipants about the high level of information provided 
and the importance of material being personally tai-
lored, future iterations should focus on simplifying the 
therapy content and working out how to best tailor it to 
participants’ situations and stage in life.
The study was not designed to test efficacy thus con-
clusions about the effects of the therapy cannot be 
drawn from the outcome data, however from the pat-
tern of results there was no strong indication of a 
detrimental effect of therapy, and where there were sig-
nificant differences between groups these favoured the 
therapy arm.
As an assessment of feasibility, a limitation of the 
current study is that qualitative feedback about the 
therapy and trial procedures was not gathered from 
all participants, with fewer than half the original sam-
ple completing the acceptability survey at 9  months. 
In particular, it is possible that those returning written 
feedback or participating in interviews may be those 
with a more positive view of the study.
Following modifications to the therapy protocol, fur-
ther feasibility testing will be necessary to establish 
whether these result in increased therapy attendance, 
before progressing to a definitive trial of the approach.
In conclusion it is broadly feasible to conduct a 
trial of this design within the population of people 
with frequent bipolar mood swings; our findings sug-
gest several areas of improvement that could be made 
to enhance recruitment and retention and to increase 
therapy accessibility and acceptability.
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